Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Beta-blockers in cirrhosis and refractory ascites : a retrospective cohort study and review of the literature. / Kimer, Nina; Feineis, Martin; Møller, Søren; Bendtsen, Flemming.
I: Scandinavian Journal of Gastroenterology, Bind 50, Nr. 2, 02.2015, s. 129-137.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Beta-blockers in cirrhosis and refractory ascites
T2 - a retrospective cohort study and review of the literature
AU - Kimer, Nina
AU - Feineis, Martin
AU - Møller, Søren
AU - Bendtsen, Flemming
PY - 2015/2
Y1 - 2015/2
N2 - OBJECTIVE: It is currently discussed if beta-blockers exert harmful effects and increase mortality in patients with cirrhosis and refractory ascites. In this study, we provide an overview of the available literature in this field in combination with a retrospective analysis of 61 patients with cirrhosis and refractory ascites in a tertiary unit.MATERIAL AND METHODS: We performed a systematic search of literature in May 2014. In addition, 61 patients with cirrhosis and ascites were identified and followed from development of refractory ascites until death or end of follow-up.RESULTS: Fourteen trials (9 trials on propranolol, 1 case-control study and 4 retrospective analyses) were identified. One trial suggested an increased mortality in patients treated with beta-blockers and refractory ascites. The results of the remaining trials were inconclusive. No increase in mortality among beta-blocker-treated patients was found in the present retrospective analysis.CONCLUSIONS: Treatment with beta-blockers may increase mortality in patients with cirrhosis and refractory ascites. However, the current evidence is sparse and high-quality studies are warranted to clarify the matter.
AB - OBJECTIVE: It is currently discussed if beta-blockers exert harmful effects and increase mortality in patients with cirrhosis and refractory ascites. In this study, we provide an overview of the available literature in this field in combination with a retrospective analysis of 61 patients with cirrhosis and refractory ascites in a tertiary unit.MATERIAL AND METHODS: We performed a systematic search of literature in May 2014. In addition, 61 patients with cirrhosis and ascites were identified and followed from development of refractory ascites until death or end of follow-up.RESULTS: Fourteen trials (9 trials on propranolol, 1 case-control study and 4 retrospective analyses) were identified. One trial suggested an increased mortality in patients treated with beta-blockers and refractory ascites. The results of the remaining trials were inconclusive. No increase in mortality among beta-blocker-treated patients was found in the present retrospective analysis.CONCLUSIONS: Treatment with beta-blockers may increase mortality in patients with cirrhosis and refractory ascites. However, the current evidence is sparse and high-quality studies are warranted to clarify the matter.
U2 - 10.3109/00365521.2014.948053
DO - 10.3109/00365521.2014.948053
M3 - Review
C2 - 25113796
VL - 50
SP - 129
EP - 137
JO - Scandinavian Journal of Gastroenterology. Supplement
JF - Scandinavian Journal of Gastroenterology. Supplement
SN - 0085-5928
IS - 2
ER -
ID: 137629650